Literature DB >> 27337967

A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.

Mohammad Ashrafuddin Khan, Mohammed I El-Gamal, Chang-Hyun Oh1.   

Abstract

B-RAF gene is a component of the MAPK pathway that plays a very important role in cell division, survival, proliferation, and many other cellular functions. Mutations of the B-RAF (such as V600E-B-RAF) lead to melanoma, which is one of the leading causes of death worldwide. R&D progress is being done aiming at improved therapy in the future. The existing melanoma therapy is left out with poor overall survival, drug resistance, and many side effects. With the recent approval of new drugs, there is a hope for melanoma patients for complete cure and better life quality. However, there is still a need for improved, safe, and complete therapy for advanced melanoma. This review describes melanoma caused by V600E-B-RAF gene mutation, its pathway, drugs available and recently approved drugs, and future prospects to be overcome.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27337967     DOI: 10.2174/1389557516666160622213142

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  3 in total

1.  The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.

Authors:  Francesca Guerrini; Matteo Paolicchi; Francesco Ghio; Elena Ciabatti; Susanna Grassi; Serena Salehzadeh; Giacomo Ercolano; Maria R Metelli; Marzia Del Re; Lorenzo Iovino; Iacopo Petrini; Giovanni Carulli; Nadia Cecconi; Martina Rousseau; Giulia Cervetti; Sara Galimberti
Journal:  Front Pharmacol       Date:  2016-10-13       Impact factor: 5.810

2.  Prognostic value of key genes of the JAK-STAT signaling pathway in patients with cutaneous melanoma.

Authors:  Fuqiang Pan; Qiaoqi Wang; Sizhu Li; Rui Huang; Xiangkun Wang; Xiwen Liao; Haiyan Mo; Liming Zhang; Xiang Zhou
Journal:  Oncol Lett       Date:  2020-01-10       Impact factor: 2.967

3.  Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.

Authors:  Zhiyang Zhou; Bi Peng; Juanni Li; Kewa Gao; Yuan Cai; Zhijie Xu; Yuanliang Yan
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.